Get to know our clinical trials
Phase 1a/1b study of ELVN-002 in combination with trastuzumab for advanced stage HER2 solid tumors and of ELVN-002 in combination with trastuzumab and chemotherapy for advanced stage HER2 colorectal cancer and HER2 breast cancer.
THE OBJECTIVE OF THIS STUDY IS TO TEST THE SAFETY AND EARLY INDICATIONS OF EFFICACY OF AN EXPERIMENTAL DRUG CALLED ELVN-002 IN COMBINATION WITH ONE OR MORE OTHER DRUGS FOR THE TREATMENT OF HER-POSITIVE CANCERS.
Technical Summary
- PHASE 1A/1B STUDY OF ELVN-002 IN COMBINATION WITH TRASTUZUMAB FOR ADVANCED STAGE HER2 SOLID TUMORS AND OF ELVN-002 IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY FOR ADVANCED STAGE HER2 COLORECTAL CANCER AND HER2 BREAST CANCER.
- Code EudraCT: 2023-509716-29-00
- Protocol number: ELVN-002-003
- Promoter: Enliven Therapeutics, Inc
- Molecule/Drug: ELVN-002
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.